Novel CNS Biomarker Day

Tuesday, February 21, 2023

As advances in biomarkers catapult our ability to monitor disease processes in neurodegeneration, a thorough grounding in the latest research is vital to ensuring optimized pipeline progression. With markers to implement in trials ranging from wearables to serum studies, efficacious therapeutics are coming closer into view. Understanding these innovations will enable the creation of validated, applicable, and quantitative resources to allow improved patient identification, observation of therapeutic response, and streamlined approval of drugs.

10:15 am Chair’s Introduction: Overviewing the Positioning of CNS Biomarkers in Neurodegenerative Diseases

  • Jian Yang Associate Vice President, Digital Health Research & Development, Eli Lilly & Co.

10:30 am Utilizing Digital Biomarkers in Clinical Research

  • Jian Yang Associate Vice President, Digital Health Research & Development, Eli Lilly & Co.

Synopsis

  • Exploring digital biomarkers as a non-invasive technology to measure neurodegenerative disorders
  • Assessing novel capabilities to precisely monitor disease progression
  • Incorporating digital biomarkers into neurodegenerative trials

11:00 am Advances in Blood Plasma Biomarkers for ALS & Alzheimer’s Disease

Synopsis

  • Brain Chemistry Labs has developed unique biomarkers for ALS and Alzheimer’s Disease that are independent of any drug being tested
  • L1CAM immunoaffinity improves miRNA data reproducibility in a broad ALS population.
  • The concentration of a blood metabolite reliably distinguishes early-stage Alzheimer’s Disease patients

11:30 am Building a Data-Driven Platform to Discover Novel Digital Biomarkers for Neurodegenerative Diseases

Synopsis

  • Exploring the development of a home-grown, data-driven computational platform
  • Handling continuous data injection from wearable technology: upholding data quality and benchmarks
  • Digital biomarker technologies available for clinical research

12:00 pm Panel Discussion: Highlighting Strategies to Incorporate Biomarkers into Neurodegenerative Clinical Trials

  • Jian Yang Associate Vice President, Digital Health Research & Development, Eli Lilly & Co.
  • Hiu Zhang Senior Director, Eli Lilly & Co.
  • Sandra Banack Senior Scientist, Brain Chemistry Labs

12:30 pm
Lunch & Networking

1:30 pm Updates on CSF Biomarker Assays for Parkinson’s Disease

Synopsis

  • Exploring use of α-synucelin RT-QuIC assays of cerebrospinal fluid for Parkinson’s Disease
  • Improving assays to dramatically reduce reaction times to diagnose Parkinson’s Disease
  • Assessing suitability for incorporation into clinical disease diagnosis

2:00 pm Exploring a Forward-Looking Biomarker Strategy for Parkinson’s: a Funder’s Perspective

  • Luis Miguel Oliveira  Senior Associate Director - Research Programs, The Michael J. Fox Foundation for Parkinson's Research

Synopsis

  • Outlining MJFF’s strategy in funding biomarker and imaging programs against Parkinson’s Disease
  • Exploring funded programs in biomarkers to support therapeutic trials
  • Showcasing funded programs to develop and validate PET imaging techniques

2:30 pm Therapeutic Response Biomarkers Based on Neuronal-Origin Extracellular Vesicles

  • Dimitrios Kapogiannis Senior Investigator, Chief, Human Neuroscience Section, NIA/NIH, Adjunct Associate Professor, Department of Neurology, Johns Hopkins Medicine, NINDS/NIH

Synopsis

  • The methodological basis of isolating Neuronal-Origin Extracellular Vesicles (NEVs)
  • NEVs provide biomarkers for prediction, diagnosis, and disease monitoring of AD and ADRD
  • NEVs provide biomarkers for participant selection and outcomes for clinical trials

3:00 pm Panel Discussion: What is the Future for Novel CNS Biomarkers?

  • Dimitrios Kapogiannis Senior Investigator, Chief, Human Neuroscience Section, NIA/NIH, Adjunct Associate Professor, Department of Neurology, Johns Hopkins Medicine, NINDS/NIH
  • Rachel Angers Associate Director, UCB S.A.
  • Luis Miguel Oliveira  Senior Associate Director - Research Programs, The Michael J. Fox Foundation for Parkinson's Research

3:30 pm Roundtable Discussion: Discourse on the Future of Biomarker Research & Applications of Novel Technologies

Synopsis

Join conversations with your fellow peers to discuss the benefits and challenges of novel neurodegenerative biomarkers. Join tables discussing neurodegenerative disease prediction, diagnosis, patient selection and implementation into Alzheimer’s and Parkinson’s trials.

  • Digital
  • Blood Plasma & CSF
  • Imaging
  • Neuronal Extracellular Vesicles

4:00 pm Summary Panel Discussion

Synopsis

Hear from your Biomarker Day speakers as they summarize and share their thoughts on the novel content covered and their insights on the future of the field for CNS biomarkers

4:45 pm Chair’s Closing Remarks

  • Jian Yang Associate Vice President, Digital Health Research & Development, Eli Lilly & Co.